Liver transplantation: Current status and novel approaches to liver replacement

被引:163
作者
Keeffe, EB
机构
[1] Stanford Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA
[2] Stanford Univ, Med Ctr, Liver Transplant Program, Stanford, CA 94305 USA
关键词
D O I
10.1053/gast.2001.22583
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The major challenge currently facing liver transplantation is the performance of a greater number of liver transplants, which has been fueled by the large and growing disparity between the increasing number of qualified patients listed for transplantation and the relatively static number of available cadaver donor organs. In the past 2 years, approximately 4500 liver transplants have been performed annually, with 1-year survival rates in the 85%-90% range, while the waiting list has expanded as of November 2000 to more than 16,000 patients, resulting in an increasing death rate among listed patients. In the short term, there will continue to be a major focus on more effective use of available cadaver donor organs to balance the competing principles of justice (patients with most urgent need for transplant and lower probability of posttransplant survival) and medical utility (patients with less urgent need for transplant and higher odds of postoperative survival). Over the long term, there will be an increasing application of novel approaches to liver replacement including cadaver split liver transplantation and adult living donor liver transplantation and possibly, in the more distant future, xenotransplantation and hepatocyte transplantation. The treatment, and ideally the prevention, of recurrent disease after liver transplantation, particularly chronic hepatitis C-the most common indication for transplantation-is a major priority to optimize the use of liver grafts. Finally, improved immunosuppressive strategies, including movement toward minimal immunosuppression and steroid withdrawal and the development of safer and move effective drugs, is another important factor that has the potential to increase the success of liver transplantation.
引用
收藏
页码:749 / 762
页数:14
相关论文
共 103 条
[1]  
AHMED A, IN PRESS CHRONIC VIR
[2]   Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B [J].
Angus, PW ;
McCaughan, GW ;
Gane, EJ ;
Crawford, DHG ;
Harley, H .
LIVER TRANSPLANTATION, 2000, 6 (04) :429-433
[3]  
[Anonymous], 1994, Lancet, V344, P423
[4]  
[Anonymous], 1984, HEPATOLOGY, V4, p107S, DOI 10.1002/hep.1840040725
[5]  
[Anonymous], 1964, LIVER PORTAL HYPERTE
[6]  
BERNUAU J, 1991, HEPATOLOGY, V14, pA49
[7]   Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation [J].
Bizollon, T ;
Palazzo, U ;
Ducerf, C ;
Chevallier, M ;
Elliott, M ;
Baulieux, J ;
Pouyet, M ;
Trepo, C .
HEPATOLOGY, 1997, 26 (02) :500-504
[8]   Health-related quality of life after liver transplantation: A meta-analysis [J].
Bravata, DM ;
Olkin, I ;
Barnato, AE ;
Keeffe, EB ;
Owens, DK .
LIVER TRANSPLANTATION AND SURGERY, 1999, 5 (04) :318-331
[9]  
BROELSCH CE, 1990, SURG GYNECOL OBSTET, V171, P353
[10]   APPLICATION OF REDUCED-SIZE LIVER-TRANSPLANTS AS SPLIT GRAFTS, AUXILIARY ORTHOTOPIC GRAFTS, AND LIVING RELATED SEGMENTAL TRANSPLANTS [J].
BROELSCH, CE ;
EMOND, JC ;
WHITINGTON, PF ;
THISTLETHWAITE, JR ;
BAKER, AL ;
LICHTOR, JL .
ANNALS OF SURGERY, 1990, 212 (03) :368-377